Supplementary Online Content

- Nugent J, Aklilu A, Yamamoto Y, et al. Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19. *JAMA Netw Open.* 2021;4(3):e211095. doi:10.1001/jamanetworkopen.2021.1095
- **eTable 1.** Characteristics of Included Patients and Patients Who Were Excluded Due to Lack of Serum Creatinine Measurement After Hospital Discharge
- **eTable 2.** Inverse Propensity-Weighted Model of eGFR Slope After Hospital Discharge for Patients with COVID-19 AKI and COVID-19 Negative AKI
- **eTable 3.** Joint Model of eGFR Slope After Hospital Discharge for Patients with COVID-19 AKI and COVID-19 Negative AKI
- **eTable 4.** Mean eGFR Slope After Hospital Discharge by COVID-19 Status Using Rolling Baseline Definition of AKI (N=1219)
- **eFigure 1.** Time to AKI Recovery After Hospital Discharge for Patients Who Had Not Returned to Baseline Kidney Function by Discharge
- **eFigure 2.** Measurement of Serum Creatinine at Different Time Points From Baseline to Six Months After Hospital Discharge for the Subgroup of Patients Who Had Not Returned to Baseline Kidney Function by Discharge

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Characteristics of Included Patients and Patients who were Excluded due to Lack of Serum Creatinine Measurement after Hospital

Discharge

Variables	Included Patients (N=1612)	Excluded Patients (N=2056)	p-value
Demographics			•
Age, years	69.7 (58.9,78.9)	69.3 (56.3,80.9)	0.63
Sex, Female	813 (50.4%)	1007 (49%)	0.38
Race, Black	298 (18.5%)	409 (19.9%)	0.28
Ethnicity, Hispanic	166 (10.3%)	294 (14.3%)	<0.001
Body mass index, kg/m²	28.3 (24.1,34.5)	28.1 (23.7,34.1)	0.07
Comorbidities			
Congestive heart failure	784 (48.6%)	806 (39.2%)	<0.001
Chronic obstructive pulmonary disease	749 (46.5%)	855 (41.6%)	0.003
Liver disease	389 (24.1%)	419 (20.4%)	0.007
Chronic kidney disease	561 (34.8%)	531 (25.8%)	<0.001
Hypertension	1429 (88.6%)	1706 (83%)	<0.001
Diabetes mellitus	838 (52%)	985 (47.9%)	0.01
Elixhauser comorbidity score	9 (5,12)	7 (4,11)	<0.001
Baseline Kidney Function			
Baseline creatinine, mg/dL	1.1 (0.8,1.4)	1 (0.8,1.4)	0.02
Baseline eGFR, mL/min/1.73m ²	64.3 (43.6,86.4)	66.2 (43.8,91.3)	0.01
Hospitalization Factors			
Proteinuria on admission	331 (20.5%)	411 (20%)	0.61
Peak creatinine, mg/dL	1.7 (1.3,2.4)	1.6 (1.2,2.2)	<0.001
Stage 1 AKI	1215 (75.4%)	1591 (77.4%)	0.15
Stage 2 AKI	267 (16.6%)	326 (15.9%)	0.56
Stage 3 AKI	130 (8.1%)	139 (6.8%)	0.13
Dialysis requirement	24 (1.5%)	34 (1.7%)	0.69
Duration of inpatient dialysis, days	7.1 (1.1,15.7)	7 (1.5,22.6)	0.65
Length of hospital stay, days	7.6 (4.3,13.5)	8 (4.5,15.5)	0.004
AKI recovery at discharge	1293 (80.2%)	1640 (79.8%)	0.74
Duration of in-hospital AKI, days	1.2 (0.8,2.2)	1.1 (0.8,2.1)	0.14
ICU admission	603 (37.4%)	802 (39%)	0.32
Length of ICU stay, days	3.8 (1.9,7.3)	3.9 (1.8,9.6)	0.15
Ventilator requirement	218 (13.5%)	338 (16.4%)	0.01
Vasopressor requirement	310 (19.2%)	421 (20.5%)	0.35
Discharge creatinine, mg/dL	1.1 (0.8,1.6)	1 (0.8,1.4)	<0.001
Discharge eGFR, mL/min/1.73m ²	59.5 (38.2,86.1)	68.3 (45.4,93.8)	<0.001
Delta creatinine (discharge – baseline), mg/dL	0 (-0.2,0.3)	0 (-0.2,0.2)	<0.001
ACEi or ARB at discharge	334 (20.7%)	407 (19.8%)	0.50
Loop diuretic administration		873 (42.5%)	<0.001
Systemic corticosteroid administration		450 (21.9%)	0.30

eGFR, estimated glomerular filtration rate; AKI, acute kidney injury, ICU intensive care unit; ACEi, ACE-inhibitor; ARB, angiotensin receptor blocker

Data expressed as median (IQR) or No. (%).

eTable 2. Inverse Propensity-Weighted Model of eGFR Slope After Hospital Discharge for Patients with COVID-19 AKI and COVID-19 negative AKI

	Unadjusted mean eGFR slope (95% CI)	p- value	Adjusted mean eGFR slope * (95% CI)	p- value	Adjusted mean eGFR slope ** (95% CI)	p- value
Difference in Slope	-12.1 (-23.8, -0.4)	0.04	-13.3 (-25.2, -1.3)	0.03	-14.9 (-26.7, -3.1)	0.01
COVID+ AKI	-12.1 (-23.0, -1.1)		-17.4 (-45.5, 10.8)		-17.2 (-45.0, 10.6)	
COVID- AKI	0.05 (-4.1, 4.2)		-4.1 (-29.4, 21.2)		-2.3 (-27.3, 22.6)	

eGFR, estimated glomerular filtration rate (mL/min/1.73m²/yr); AKI, acute kidney injury; CI, confidence interval
* adjusted for age, sex, race, body mass index, hospital of admission, baseline eGFR, Elixhauser comorbidity score, congestive heart failure, hypertension, diabetes mellitus

^{**} adjusted for * plus peak creatinine and dialysis requirement

eTable 3. Joint Model of eGFR Slope After Hospital Discharge for Patients with COVID AKI and COVID-negative AKI						
	Unadjusted mean eGFR slope (95% Bayesian Credible Interval)	p- value	Adjusted mean eGFR slope * (95% Bayesian Credible Interval)	p- value	Adjusted mean eGFR slope ** (95% Bayesian Credible Interval)	p- value
Difference in Slope	-10.0 (-17.8, -2.3)	0.009	-10.9 (-19.1, -3.0)	0.007	-12.2 (-19.8, -4.2)	0.002
COVID+ AKI	-11.0 (-18.3, -3.7)		-10.0 (-23.4, 3.3)		-11.1 (-24.3, 2.4)	
COVID- AKI	-1.0 (-3.7, 1.9)		0.9 (-10.0, 11.3)		1.1 (-9.4, 12.1)	
Association parameter	-0.005 (-0.01, 0.003)	0.24	-0.005 (-0.01, 0.003)	0.39	-0.01 (-0.03, 0.01)	0.26

eGFR, estimated glomerular filtration rate (mL/min/1.73m²/yr); AKI, acute kidney injury; CI, confidence interval
* Both submodels in the joint model (linear mixed model and survival mixed model) were adjusted for age, sex, race, body mass index, hospital of admission, baseline eGFR, Elixhauser comorbidity score, congestive heart failure, hypertension, diabetes mellitus
** Both submodels were adjusted for * plus peak creatinine and dialysis requirement

eTable 4. Mean eGFR Slope After Hospital Discharge by COVID-19 Status Using Rolling Baseline Definition of AKI (N=1219)¹

(14 1210)						
	Unadjusted mean eGFR slope (95% CI)	p- value	Adjusted mean eGFR slope * (95% CI)	p- value	Adjusted mean eGFR slope ** (95% CI)	p- value
Difference in Slope	-10.8 (-23.5, 1.9)		-12.9 (-26.2, 0.3)		-14.5 (-27.5, -1.5)	
COVID+ AKI	-9.4 (-21.2, 2.3)	0.09	-24.7 (-56.5, 7.2)	0.06	-24.4(-55.7, 6.9)	0.03
COVID- AKI	1.4 (-3.4, 6.3)		11.7 (-40.5, 17.0)		-9.9 (-38.1, 18.3)	


eGFR, estimated glomerular filtration rate (mL/min/1.73m²/yr); AKI, acute kidney injury; CI, confidence interval

¹A total of 34 COVID+ patients and 359 COVID- patients were excluded from this sensitivity analysis due to meeting AKI criteria based on their prehospital outpatient baseline creatinine but not based on the rolling baseline approach.

^{*} adjusted for age, sex, race, body mass index, hospital of admission, baseline eGFR, Elixhauser comorbidity score, congestive heart failure, hypertension, diabetes mellitus


^{**} adjusted for * plus peak creatinine and dialysis requirement

eFigure 1. Time to AKI Recovery after Hospital Discharge for Patients who had not Returned to Baseline Kidney Function by Discharge



Survival curves for time to AKI recovery after discharge, defined as a serum creatinine <1.5 times the baseline creatinine, are shown for the subgroup of patients who had not achieved AKI recovery by the time of discharge from the hospital (n=319). AKI, acute kidney injury

eFigure 2. Measurement of Serum Creatinine at Different Time Points from Baseline to Six Months after Hospital Discharge for the Subgroup of Patients who had not Returned to Baseline Kidney Function by Discharge



Mean (SE) serum creatinine measurements are shown at different time points from baseline to six months after hospital discharge for the subgroup of patients who had not returned to baseline kidney function by discharge.

AKI, acute kidney injury; SE, standard error